Form 4: Apellis Pharmaceuticals Acquired by Biogen

Director Craig A. Wheeler reports the disposition of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.

Summary

• Apellis Pharmaceuticals, Inc. has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• The transaction was finalized on May 14, 2026, with Apellis becoming a wholly-owned subsidiary of Biogen.
• Shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 upon the achievement of specific milestones.
• Director Craig A. Wheeler disposed of all direct holdings, including 24,444 shares of common stock and various stock options, as part of the merger consideration.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit and potential upside through CVRs.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share based on future milestones.
• The acquisition provides a clear exit strategy for equity holders at a set valuation.

Negatives

• The company is no longer an independent publicly traded entity.
• Future growth potential for current shareholders is limited to the CVR milestones.

Risks

• The $4.00 CVR payment is contingent upon specific milestones, which may not be achieved.
• The CVR is non-transferable, limiting liquidity for the holder.

Future Outlook

The company has been acquired and is now a wholly-owned subsidiary of Biogen; future operations will be integrated into the parent company.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects ongoing consolidation in the biopharmaceutical sector, where larger entities like Biogen are acquiring specialized firms to bolster their pipelines, particularly in rare disease or ophthalmology segments.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biopharma M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The $41.00 cash offer represents the final valuation for the independent entity.

Corporate Governance

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees may face organizational restructuring due to the merger.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Tender Offer, Contingent Value Right, CVR